The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 29, 2025

Filed:

Dec. 19, 2019
Applicant:

Oslo Universitetssykehus Hf, Oslo, NO;

Inventors:
Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 19/00 (2005.12); A61K 39/00 (2005.12); A61P 35/04 (2005.12); C07K 14/705 (2005.12); C07K 16/30 (2005.12); C12N 5/0783 (2009.12); C12N 15/62 (2005.12);
U.S. Cl.
CPC ...
C12N 5/0636 (2012.12); A61K 39/4611 (2023.04); A61K 39/4631 (2023.04); A61K 39/4644 (2023.04); A61P 35/04 (2017.12); C07K 14/70517 (2012.12); C07K 14/70532 (2012.12); C07K 16/30 (2012.12); C12N 15/62 (2012.12); A61K 2039/86 (2018.07); A61K 2239/31 (2023.04); A61K 2239/55 (2023.04); C07K 2317/622 (2012.12); C07K 2317/73 (2012.12); C07K 2319/03 (2012.12); C07K 2319/33 (2012.12);
Abstract

Chimeric antigen receptors (CARs) are provided. When the CARs herein are expressed on the surface of immune cells, such immune cells may be directed to osteosarcoma cells. In a murine intraperitoneal model, the tumor growth was significantly delayed for T cells expressing a CAR comprising a scFv from TP1 or TP3 antibodies. Immune cells expressing the CARs herein display therapeutic effect in the form of decreased tumor volume in a murine model simulating metastatic osteosarcoma. Combined with the finding that stem cells from healthy bone marrow were not significantly affected by T cells expressing any of the CARs, the CARs may be used for the treatment of osteosarcoma.


Find Patent Forward Citations

Loading…